Home > Insider Trading > Filing (0001209191-22-053357)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649989	Outlook Therapeutics Inc.	OTLK	Biological Products, (No Disgnostic Substances) (2836)	383982704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1716033	Ghiath Faisal Sukhtian	C/O Outlook Therapeutics, Inc. 485 Route 1 South, Building F, Suite 320 Iselin NJ 08830		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-10-07	30,000	$1.29	68,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 - $1.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
Reflects the amount of securities beneficially owned by the Reporting Person following the reported transaction herein and corrects the erroneous Form 4 filed with the Securities and Exchange Commission on April 22, 2022 (the "April 22, 2022 Filing"), pursuant to which a total of 55,816,786 shares were reported as indirectly beneficially owned (by GMS Ventures) on Table I. These shares are indirectly beneficially owned by Ghiath M. Sukhtian (CIK number 0001717441) and not by the Reporting Person. The April 22, 2022 Filing was erroneously made under the Reporting Person's CIK number.